Nurix Therapeutics (NRIX) Proxy filing summary

Executive summary

• Advanced lead BTK degrader, bexobrutideg, into pivotal Phase 2 and planned Phase 3 trials for CLL, showing strong efficacy and safety in clinical data presented at ASH 2025.

• Expanded pipeline in oncology and immunology, including progress in partnered programs with Sanofi and Gilead, and strengthened financial position with $592.9M in cash and a $250M equity offering.

• Strategic priorities for 2026 include advancing bexobrutideg in CLL and I&I, supporting partnered programs, and expanding the pipeline.

Voting matters and shareholder proposals

• Election of three Class III directors for three-year terms.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.

• Advisory vote on executive compensation (say-on-pay).

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board is divided into three staggered classes; separation of CEO and Chair roles.

• Majority of directors are independent; annual self-evaluations conducted with third-party facilitation.

• Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Clinical and Commercialization.

• Board and committees met regularly in 2025, with high attendance.